Assay\isolate | Blood culture isolate* | Kp0003 | Ec0004 (Ec0002 transconjugant) | Ec0002 |
---|---|---|---|---|
Antibiotic | MIC (mg/L) | |||
Ampicillin | R | ≥32R | ≥32R | ≤2S |
Amoxicillin/CLA | ≥32R | ≥32R | ≤2S | |
Ticarcillin/CLA | ≥128R | ≥128R | ≤8S | |
Piperacillin/TZB | R | ≥128R | ≥128R | ≤4S |
Cefazolin | R | ≥64R | ≥64R | ≤4S |
Cefoxitin | ≥64R | ≥64R | ≤4S | |
Ceftazidime | ≥64R | ≥64R | ≤1S | |
Ceftriaxone | R | ≥64R | ≥64R | ≤1S |
Cefepime | R | ≥64R | 4I | ≤1S |
Meropenem | R | ≥16R | ≥16R | ≤0.25S |
Amikacin | S | ≤2S | ≤2S | ≤2S |
Gentamicin | R | ≥16R | ≤1S | ≤1S |
Tobramycin | ≥16R | ≤1S | ≤1S | |
Ciprofloxacin | R | ≥4R | ≤1S | ≤1S |
Norfloxacin | ≥16R | ≤0.5S | ≤0.5S | |
Trimethoprim | R | ≥16R | ≤0.5S | ≤0.5S |
Trimethoprim/SXT | ≥320R | ≤20S | ≤20S | |
Gene target† | PCR results | |||
blaNDM-4 | + | + | − | |
IncX3 taxC | + | + | − | |
IncFII repA | + | − | − |
*Original blood culture isolate susceptibilities as per the report received from Mynamar.
†blaNDM-4 was amplified using primers NDM-F: 5′-atggaattgcccaatattatg-3′ and NDM-R: 5′-ccggggtaaaataccttg-3′. Primers to detect IncX39 and IncFII10 were published elsewhere.
CLA, clavulanic acid; I, intermediate; R, resistant; S, sensitive; SXT, sulfamethoxazole; TZB, tazobactam.